Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

What's fueling the biotech engine—2007

Nature Biotechnology volume 26, pages 1227–1233 (2008)Cite this article

A Corrigendum to this article was published on 01 February 2009

An Erratum to this article was published on 01 February 2009

This article has been updated

Despite losses in revenue from erythropoietins, historically the highest earner of all biologics, more than 100 biotech drugs continued their upward trend in sales begun in 2006, with antibodies and insulin analogs fueling growth at double-digit rates.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2: Top 11 companies that comprise the majority of sales of biologic drugs in 2007.
Figure 3: Top ten categories of biologic drugs in terms of US sales in 2007.
Figure 4: Trends in US sales of mAbs.
Figure 5: Trends in US sales of growth factors.
Figure 6: Trends in US sales of recombinant hormones.
Figure 7: US sales of recombinant cytokines and recombinant vaccines.
Figure 8: US sales of blood factors, therapeutic enzymes and anti-coagulants.

Change history

  • 09 February 2009

    In the version of this article initially published, 2007 US sales of therapeutic enzymes in Figure 3 were incorrectly listed as $0.7 billion. They should be $0.9 billion. In the same figure, the 2007 growth (%) was incorrectly listed as –14%; it should be 18%. On page 1230, human growth hormone sales growth rate was incorrectly reported as 45%; it should be 5%. The errors have been corrected in the PDF and HTML versions of this article.

  • 09 February 2009

    In the version of this article initially published, in Figure 5, the $2.40 billion pie section was mislabeled as Rituxan. It should be Procrit. The error has been corrected in the PDF and HTML versions of this article.

References

  1. Long, D., US Pharmaceutical Market: Trends, Issues, Outlook, IMS Health, Norwalk, CT, USA (April 8, 2008).

  2. Aggarwal, S. Nat. Biotechnol. 25, 1097–1104 (2007).

    Article  CAS  Google Scholar 

  3. Ricklin, D. & Lambris, J.D. Nat. Biotechnol. 25, 1265–1275 (2007).

    Article  CAS  Google Scholar 

  4. Steinbrook, R. N. Engl. J. Med. 356, 2448–2451 (2007).

    Article  CAS  Google Scholar 

  5. Schneider, C.K. & Kalinke, U. Nat. Biotechnol. 26, 985–990 (2008).

    Article  CAS  Google Scholar 

  6. Mack, G.S. Nat. Biotechnol. 25, 1331–1332 (2007).

    Article  CAS  Google Scholar 

  7. Ratner, M. Nat. Biotechnol. 26, 485 (2008).

    Article  CAS  Google Scholar 

  8. Kuter, D.J. Eur. J. Haematol. Suppl. 69, 9–18 (2008).

    Article  CAS  Google Scholar 

  9. Johnston, M.I. & Fauci, A.S. N. Engl. J. Med. 359, 888–890 (2008).

    Article  CAS  Google Scholar 

  10. Kim, J.J. & Goldie, S.J. N. Engl. J. Med. 359, 821–832 (2008).

    Article  CAS  Google Scholar 

  11. Lanthier, M, Behrman, R, and Nardinelli, C., Economic issues with follow-on protein products Nature Reviews Drug Discovery, 7, 733–737 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Saurabh Aggarwal is a healthcare consultant based in New York. saurabhaggarwal@gmail.com,

    Saurabh Aggarwal

Authors
  1. Saurabh Aggarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aggarwal, S. What's fueling the biotech engine—2007. Nat Biotechnol 26, 1227–1233 (2008). https://doi.org/10.1038/nbt1108-1227

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1108-1227

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing